Blood cancer Patients' immune system under microscope for COVID-19 clues
NCT ID NCT07204366
First seen Nov 01, 2025 · Last updated May 21, 2026 · Updated 19 times
Summary
This study examines whether people with certain blood cancers (myeloproliferative neoplasms) have autoantibodies that block a key immune protein, type I interferon. Researchers want to see how common these autoantibodies are and if they relate to worse COVID-19 outcomes. About 219 adults with these blood cancers will provide a blood sample for analysis. The study does not test a new treatment but aims to understand why some patients get severely ill from COVID-19.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Fondazione IRCCS Policlinico San Matteo
Pavia, Lombardy, 27100, Italy
Conditions
Explore the condition pages connected to this study.